patients. answers. results. - arup laboratories...patients.answers.results. hematopathology testing...

PATIENTS.ANSWERS.RESULTS.

hematopathology testing

Information in this brochure is current as of October 2018. All content is subject to change. Please contact ARUP Client Services at (800) 522-2787 with any questions or concerns.

OCTOBER 2018www.aruplab.com

patients. answers. results.A laboratory test is more than a number; it is a person, an answer, a diagnosis.

ARUP LABORATORIESAs a nonprofit, academic institution of the University of Utah and its Department of Pathology, ARUP believes in collaborating, sharing knowledge, and contributing to laboratory science in ways that benefit our clients and their patients.

Our test menu is one of the broadest in the industry, encompassing more than 3,000 tests, including highly specialized and esoteric assays. We offer comprehensive testing in the areas of genetics, molecular oncology, pediatrics, and pain management, among others.

ARUP’s clients include many of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, and group purchasing organizations. We do not compete with our clients for physician office business, choosing instead to support clients’ existing test menus by offering highly complex assays and accompanying consultative support so clients can provide exceptional patient care in their local communities.

Offering analytics, consulting, and decision support services, ARUP provides clients with the utilization management tools necessary to prosper in this time of value-based care. Our UM+ program helps clients control utilization, reduce costs, and improve patient care. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.

ARUP’s reputation for quality is supported by our ability to meet or exceed the requirements of multiple regulatory and accrediting agencies and organizations. ARUP participates in the CAP laboratory accreditation program and has CLIA certification through the Centers of Medicare and Medicaid Services. In December 2016, ARUP earned accreditation to the ISO 15189:2012 standard under CAP.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

We believe in collaborating, sharing knowledge, and contributing to laboratory science in ways that provide the best value for the patient. Together, ARUP and its clients will improve patient care today and in the future.

The ARUP Hematopathology Laboratory and Hematopathology Division offer diagnostic consultative services and a comprehensive test menu for the evaluation of hematologic disorders. The division consists of nationally and internationally known medical professionals whose expertise spans many different subspecialties of hematopathology, including flow cytometry, immunohistochemistry, cytogenetics, coagulation, and molecular diagnostics. An integrated approach is utilized to provide clients with services ranging from test interpretation and selection to comprehensive histomorphologic diagnosis. For information regarding hematopathology consultation, please call (801) 581-5854.

Archana Mishra Agarwal, MDMedical Director, Hematopathology and Special Genetics Dr. Agarwal is an associate professor of pathology at the University of Utah School of Medicine. She received her MD at Delhi University in India and was a postdoctoral research scholar at the University of Iowa. She served as a pathology resident, a hematopathology fellow, and a molecular genetics pathology fellow at the University of Utah School of Medicine. Dr. Agarwal is board certified in hematopathology, anatomic pathology, and clinical pathology. She is also a member of several professional societies, including the College of American Pathologists and the American Society

for Clinical Pathology. Dr. Agarwal’s research interests include red-cell enzymopathies, hemoglobinopathies, and molecular hematopathology.

Bo Hong, MD, FACMGMedical Director, Cytogenetics and Genomic MicroarrayDr. Hong is an assistant professor of pathology at University of Utah School of Medicine. She received her MD at Beijing Medical University in Beijing, China, and completed a residency in internal medicine and hematology at People’s Hospital, Beijing Medical University, and a clinical cytogenetics fellowship at the University of Utah. Her academic interests include the clinical significance of cytogenetic findings in hematologic malignancies, particularly in pediatric leukemia and treatment-related leukemia.

Erica Andersen, PhD, FACMGMedical Director, Cytogenetics and Genomic MicroarrayDr. Andersen is an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in genetics from the University of Wisconsin–Madison and completed a clinical cytogenetics fellowship at the University of Utah. She is board certified by the American Board of Medical Genetics and Genomics and Genomics and is a fellow of the American College of Medical Genetics and Genomics. Dr. Andersen’s interests include both constitutional and oncology cytogenetics. She is an active member of the Clinical Genome Resource (ClinGen) group’s

efforts to improve constitutional structural variant interpretation, and her oncology research projects include improving the diagnosis and monitoring for myelodysplastic syndromes and understanding the genetic etiology of rare histiocytic and dendritic cell neoplasms.

Kristin Hunt Karner, MDMedical Director, Hematopathology; Medical Director, Molecular Oncology; Director, Hematopathology Fellowship ProgramDr. Karner is an assistant professor of pathology at the University of Utah School of Medicine. She received her MD from the University of Nebraska and completed her anatomic and clinical pathology residency at the University of New Mexico. She also completed hematopathology and molecular genetic pathology fellowships at the University of New Mexico and is board certified by the American Board of Pathology in anatomic and clinical pathology (AP/CP), as well as hematopathology and

molecular genetic pathology. Dr. Karner’s areas of focus include both lymphoid and myeloid malignancies, and her current research interests include genetic aspects of myelodysplastic syndrome and other myeloid malignancies.

David W. Bahler, MD, PhDMedical Director, HematopathologyDr. Bahler is an associate professor of pathology at the University of Utah School of Medicine. He is certified by the American Board of Pathology in clinical pathology, with an added qualification in hematology. Dr. Bahler received his PhD in immunology and his MD from the University of Rochester. His research interests include the role of antigen receptor stimulation in the development of lymphoid malignancies.

Allen N. Lamb, PhD, FACMGSection Chief, Cytogenetics and Genomic MicroarrayDr. Lamb is a professor of clinical pathology at the University of Utah School of Medicine. He received his PhD from Wesleyan University in molecular biology and biochemistry. He completed fellowships in clinical cytogenetics in the Department of Pediatrics at the University of North Carolina and in clinical molecular genetics at Harvard Medical School. Dr. Lamb is a founding fellow of the American College of Medical Genetics and Genomics and is certified by the American Board of Medical Genetics and Genomics in clinical cytogenetics. His primary areas of interest are in

prenatal and postnatal chromosome diagnosis and the characterization of the phenotypic features (neurodevelopmental and physical development) associated with copy number changes.

Julie Leana Cox, PhD, FACMGMedical Director, CytogeneticsDr. Cox is board certified by the American Board of Medical Genetics and Genomics and Genomics and is a diplomate in both clinical cytogenetics and clinical molecular genetics. Dr. Cox received master’s degrees in human genetics and administrative science from Johns Hopkins University and a doctorate in human genetics from the University of Maryland at Baltimore. She completed a clinical cytogenetics and clinical molecular genetics fellowship at the University of Maryland, Division of Human Genetics.

K. David Li, MDMedical Director, Hematopathology Assistant Medical Director, Hematologic Flow CytometryDr. Li is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from New York Medical College and completed a residency in anatomic and clinical pathology at the University of California, San Diego. Dr. Li also completed a fellowship in hematopathology at the University of Utah, and i s board certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology.

for more information, visit:

HEMATOPATHOLOGY EXPERTISE

Tracy I. George, MDExecutive Director, Clinical Trials and PharmaDxMedical Director, HematopathologyDr. George is a professor of pathology at the University of Utah School of Medicine. She completed her MD and residency training in anatomic pathology and laboratory medicine at the University of California San Francisco, with fellowships in hematopathology and surgical pathology at Stanford University. Dr. George is board certified in anatomic pathology, clinical pathology, and hematology by the American Board of Pathology. Her research interests include mast cell disease and laboratory

hematology. Dr. George has authored more than 100 publications, is Vice President of Scientific Communications for the International Society for Laboratory Hematology, and Co-Editor-in-Chief of the International Journal of Laboratory Hematology. She received the College of American Pathologists Lifetime Achievement Award in 2014.

Rodney R. Miles, MD, PhDSection Chief, HematopathologyMedical Director, Hematologic Flow CytometryDr. Miles is an associate professor of pathology at the University of Utah School of Medicine. He received his MD and a PhD in cell biology from the University of Nebraska and is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology. His research interests include biological subtypes of adult and pediatric non-Hodgkin lymphomas. Dr. Miles is a member the American Society of Hematology, the Society for Hematopathology, and the United

States and Canadian Academy of Pathology.

5www.aruplab.com/hematopathology

HEMATOPATHOLOGY EXPERTISE

Karen Moser, MDMedical Director, Hemostasis/ThrombosisDr. Moser is an assistant professor of pathology at the University of Utah School of Medicine. She received her M.D. from Saint Louis University and subsequently served as a pathology resident and hematopathology fellow at the University of Utah School of Medicine. She is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology. Dr. Moser is a member of several professional societies, including the College of American Pathologists (for which she serves as a member of the Standards and Coagulation

Resource Committees), American Society for Clinical Pathology, and International Society on Thrombosis and Haemostasis. Her primary research interest is in laboratory hemostasis and thrombosis testing.

George M. Rodgers III, MD, PhDMedical Director, Hemostasis/ThrombosisDr. Rodgers is a professor of medicine and pathology at the University of Utah School of Medicine. He received his PhD in pharmacology and his MD from the Tulane University School of Medicine and is certified in internal medicine by the American Board of Internal Medicine a nd in hematology by the American Board of Pathology. Dr. Rodgers is the co-editor of Wintrobe’s Clinical Hematology.

Jay L. Patel, MDMedical Director, Molecular OncologyMedical Director, GenomicsMedical Director, HematopathologyDr. Patel is an associate professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Arizona, completed a residency in anatomic and clinical pathology at the University of Utah, and was a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical

pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology, especially next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies.

Roger Schultz, PhD, FACMGMedical Director, Cytogenetics and Molecular CytogeneticsDr. Schultz received a master of science in biology at Wayne State University in Detroit and a PhD in genetics at Michigan State University. He completed a postdoctoral fellowship at Stanford University School of Medicine and a cytogenetics fellowship with subsequent American Board of Medical Genetics and Genomics board certification at the University of Texas Southwestern Medical Center in Dallas. Dr. Schultz is a member of several professional societies, including the American Society of Human Genetics and Association of Molecular Pathology. His research interests include chromosomal basis of human disease and development, DNA repair and cancer, and chromosome and genome stability in cancer.

Kristi J. Smock, MDMedical Director, Hemostasis/ThrombosisDr. Smock is an associate professor of pathology and associate program director of the Pathology Residency Program at the University of Utah School of Medicine. She completed her medical degree, residency, and fellowship training at the University of Utah. She is currently vice president of the North American Specialized Coagulation Laboratory Association (NASCOLA) and an editorial board member for Research and Practice in Thrombosis and Haemostasis. Dr. Smock’s primary research interest is laboratory coagulation medicine.

Denise Quigley, PhD, FACMGMedical Director, CytogeneticsDr. Quigley received her PhD in molecular and medical genetics at Oregon Health Sciences University and completed post-doctoral fellowships in clinical cytogenetics and clinical molecular genetics at the University of North Carolina, Chapel Hill. She is board certified in clinical cytogenetics and clinical molecular genetics by the American Board of Medical Genetics and Genomics and Genomics. Dr. Quigley is a member of the CAP Cytogenetics Resource Committee and past-president of the American Cytogenetics Conference. Her research interests include integrated cytogenetic and molecular genetic testing algorithms in hematological disease for accurate diagnosis, prognosis, and guided therapy.

Reha Toydemir, MD, PhD, FACMGMedical Director, Cytogenetics and Genomic MicroarrayDr. Toydemir is an assistant professor of pathology at the University of Utah, School of Medicine. He was a fellow in cytogenetics at ARUP Laboratories and a previous postdoctoral associate in the Human Genetics Department at the University of Utah. He completed his PhD in genetics at the University of Utah and his MD at the University of Ankara, School of Medicine in Turkey. Dr. Toydemir was the recipient of the 2007 James W. Prahl Award for Outstanding Contributions by a Graduate Student in the biological or biomedical science at the University of Utah, and is a member

of the American Society of Human Genetics and Turkish Society of Medical Genetics.

Sherrie L. Perkins, MD, PhDChief Executive Officer, ARUP LaboratoriesDr. Perkins, CEO of ARUP Laboratories and a professor of pathology at the University of Utah School of Medicine, has been with ARUP and the University of Utah for over 25 years and has served in numerous leadership roles. She is board certified in anatomic pathology and holds a special qualification in hematology. She has authored over 200 peer-reviewed journal articles and 70 book chapters in hematopathology. She received her PhD in biochemistry from the University of Miami, and earned her MD and completed her pathology residency at Washington University in

St. Louis. She completed her hematopathology fellowship under Dr. Carl Kjeldsberg at the University of Utah.

Anton Rets, MD, PhDMedical Director, HematopathologyDr. Rets is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD and PhD at Perm State Academy of Medicine in Russia. He served as an anatomical and clinical pathology resident at State University of New York Health Science Center at Brooklyn and a hematopathology fellow at the University of Utah School of Medicine. Dr. Rets is board certified in hematopathology, anatomic pathology, and clinical pathology. He is also a member of several professional societies, including the College of American Pathologists

and the American Society for Clinical Pathology. Dr. Rets’ professional interests are broad and include red blood cell disorders, non-neoplastic hematology, and precursor lymphoid neoplasms.

Xinjie Xu, PhD, FACMGMedical Director, Cytogenetics and Genomic MicroarrayMedical Director, Molecular Hematopathology/OncologyDr. Xu is an assistant professor of pathology at the University of Utah, School of Medicine. She received her PhD in genetics from the University of Wisconsin-Madison and completed a clinical cytogenetics fellowship at the University of Wisconsin-Madison and a clinical molecular genetics fellowship at Boston University. Dr. Xu is a fellow of the American College of Medical Genetics and Genomics and a member of several professional societies, including the American Society of Human Genetics and the

American Society of Clinical Pathology. Her research interests include the identification of novel molecular markers in cancer and the development of novel diagnostic tools for genetic testing.

6 for more information, visit:

test # test name diagnostic prognostic pharmacogenetic

Acute Lymphoblastic Leukemia (ALL)

2002647 Acute Lymphocytic Leukemia (ALL) Panel by FISH, Adult X

2002719 Acute Lymphocytic Leukemia (ALL) Panel by FISH, Pediatric X

2002298 BCR-ABL1 Fusion, t(9;22)(q34;q11.2) by Chromosome FISH, Interphase X X X

2005010 BCR-ABL1 Qualitative with Reflex to BCR-ABL1 Quantitative X X

2005016 BCR-ABL1 Minor (p190), Quantitative X X

2008420 BCR-ABL1 Mutation Analysis by Next-Generation Sequencing X

2002298 CDKN2 p16 Deletion 9p21 by Chromosome FISH, Interphase X

2007130 Chromosome Analysis, Bone Marrow with Reflex to Genomic Microarray X X

2007131 Chromosome Analysis, Leukemic Blood with Reflex to Genomic Microarray X X

2006325 Cytogenomic SNP Microarray—Oncology X

2002298 ETV6-RUNX1 (TEL-AML1) Fusion, t(12;21)(p13;q22) by Chromosome FISH, Interphase X X

2002298 Hyperdiploidy with Trisomy 4 and 10 by Chromosome FISH, Interphase X

2002298 IGH Rearrangement 14q32 by Chromosome FISH, Interphase X

0055655 Methylenetetrahydrofolate Reductase (MTHFR) 2 Mutations X

2002298 MLL Rearrangement 11q23 by Chromosome FISH, Interphase X

2002298 TCF3 (E2A) Rearrangement 19p13 by Chromosome FISH, Interphase X X

Acute Myelogenous Leukemia (AML)

2011132 Acute Myeloid Leukemia Panel by FISH X

2002653 Acute Myelogenous Leukemia (AML) with Myelodysplastic Syndrome (MDS) or Therapy-Related AML by FISH X

2002298 CBFB Rearrangement inv(16)(p13.3q22) by Chromosome FISH, Interphase X X

2011114 CBFB-MYH11 inv(16) Detection, Quantitative X X

2004247 CEBPA Mutation Detection X

2007130 Chromosome Analysis, Bone Marrow with Reflex to Genomic Microarray X X

2006325 Cytogenomic SNP Microarray—Oncology X

2014683 LeukoStrat CDx FLT3 Mutation Detection by PCR X X

2006444 IDH1 and IDH2 Mutation Analysis, Exon 4 X

2002437 KIT Mutations in AML by Fragment Analysis and Sequencing X X

2002298 MLL Rearrangement 11q23 by Chromosome FISH, Interphase X

TEST CATEGORIES



Acute Myelogenous Leukemia (AML), continued3000066 NPM1 Mutation Detection by RT-PCR, Quantitative X

2002298 RUNX1-RUNX1T1 (AML1-ETO) Fusion, t(8;21) (q22;q22) by Chromosome FISH, Interphase X X

2010138 RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Detection, Quantitative X X

2005766 WT1 Mutations by Sequencing X

2011117 Myeloid Malignancies Mutation Panel by Next-Generation Sequencing X X

2012182 Myeloid Malignancies Somatic Mutation and Copy Number Analysis Panel X X

Acute Promyelocytic Leukemia (APL)

2002363 PML-RARA Translocation by FISH X X X

2002871 PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative X X X

B- and T- Cell Markers Lymphoma

2006193 B-Cell Clonality Screening (IgH and IgK) by PCR X

2009318 MYD88 L265P Mutation Detection by PCR, Quantitative X

0055567 T-Cell Clonality Screening by PCR X

Burkitt Lymphoma

2012710 Aggressive B-Cell Lymphoma FISH Reflex, Tissue X

2010107 BCL6 (3q27) Gene Rearrangement by FISH X

2001538 IGH-MYC Fusion t(8;14) by FISH X

2002345 MYC (8q24) Gene Rearrangement by FISH X

2002298 MYC Rearrangement 8q24 by Chromosome FISH, Interphase X

Chronic Lymphocytic Leukemia (CLL)

2002295 Chronic Lymphocytic Leukemia (CLL) Panel by FISH X

0040227 IGHV Mutation Analysis by Sequencing X

Chronic Myelogenous Leukemia (CML)

2002298 BCR-ABL1 Fusion, t(9;22)(q34;q11.2) by Chromosome FISH, Interphase X X X

2008420 BCR-ABL1 Mutation Analysis by Next-Generation Sequencing X X

2005017 BCR-ABL1 Major (p210), Quantitative X X

2005016 BCR-ABL1 Minor (p190), Quantitative X X

2005010 BCR-ABL1 Qualitative with Reflex to BCR-ABL1 Quantitative X X

0055655 Methylenetetrahydrofolate Reductase (MTHFR) 2 Mutations X

TEST CATEGORIES



Follicular Lymphoma/Diffuse Large-Cell Lymphoma

2012710 Aggressive B-Cell Lymphoma FISH Reflex, Tissue X

2002298 BCL6 Rearrangement 3q27 by Chromosome FISH, Interphase X

2002298 IGH-BCL2 Fusion, t(14;18)(q32;q21) by Chromosome FISH, Interphase X

2001536 IGH-BCL2 Fusion, t(14;18) by FISH X

Hairy Cell Leukemia

2007132 BRAF V600E Mutation Detection in Hairy Cell Leukemia by Real-Time PCR, Quantitative X

Lymphoproliferative Disorders (LPD)

2002650 Lymphoma (Aggressive) Panel by FISH X

2002298 Trisomy 12 by Chromosome FISH, Interphase X

Mantle Cell Non-Hodgkins Lymphoma

2002298 IGH Rearrangement by Chromosome FISH, Interphase X

2007226 IGH-CCND1 Fusion, t(11;14) by FISH X

2002298 IGH-CCND1 Fusion, t(11;14)(q13;q32) by Chromosome FISH, Interphase X

Marginal Zone B-Cell Lymphoma

2002298 MALT1 (18q21) gene rearrangement by FISH X

Multiple Myeloma

2002294 Multiple Myeloma Panel by FISH X

Myelodysplastic Syndrome (MDS)

2002298 20q Deletion (D20S108) del(20)(q12) by Chromosome FISH, Interphase X

2002298 5q Deletion (EGR1)/Monosomy 5 del(5)(q31)/-5 by Chromosome FISH, Interphase X

2002298 7q Deletion (D7S486)/Monosomy 7 del(7)(q31)/-7 by Chromosome FISH, Interphase X

2002709 Myelodysplastic Syndrome (MDS) Panel by FISH X




TEST CATEGORIES



Myeloproliferative Neoplasms (MPN)

2010673 CALR (Calreticulin) Exon 9 Mutation Analysis by PCR X X

2002378 Eosinophilia Panel by FISH X X

2002357 JAK2 Exon 12 Mutation Analysis by PCR X

0051245 JAK2 Gene, V617F Mutation, Qualitative X

2012084JAK2 Gene, V617F Mutation, Qualitative with Reflex to CALR (Calreticulin) Exon 9 Mutation Analysis by PCR with Reflex to MPL Codon 515 Mutation Detection by Pyrosequencing, Quantitative

X X

2012085 JAK2 Gene, V617F Mutation, Qualitative with Reflex to JAK2 Exon 12 Mutation Analysis by PCR X

0040168 JAK2 Gene, V617F Mutation, Quantitative X

2005545 MPL Codon 515 Mutation Detection by Pyrosequencing, Quantitative X

2002360 Myeloproliferative Disorders Panel by FISH X

2002298 PDGFRA-FIP1L1 Fusion (CHIC2 Deletion) by Chromosome FISH, Interphase X

2002298 PDGFRB Rearrangement 5q33.1 by Chromosome FISH, Interphase X





Primary Effusion Lymphoma

2002902 Epstein-Barr Virus (EBV) by in situ Hybridization, Paraffin X

HEMATOLOGIC FLOW CYTOMETRY

test # test name

2008003 Leukemia/Lymphoma Phenotyping by Flow Cytometry

0093199 T-Cell Clonality by Flow Cytometry Analysis of TCR V-Beta

0092099 B-Cell CD20 Expression

TEST CATEGORIES


HEMATOPATHOLOGY IHC STAINS

test # test name

Immunohistochemistry Markers—Stain and Return2003439 Anaplastic Lymphoma Kinase 1 (ALK-1)

2003442 B Cell Specific Octamer Binding Protein-1 (BOB-1)

2004513 BCL-2

2003457 BCL-6

2003466 BF-1

2003502 CD1a

2003505 CD2 (AB75)

2003508 CD3

2003511 CD4 (1F6)

2003514 CD5

2003517 CD7

2003520 CD8

2003523 CD10 (CALLA)

2003526 CD14

2003529 CD15 (Leu M1)

2005114 CD19

2003532 CD20 (L26, Leu 16)

2003535 CD21 (Dendritic Cell)

2003541 CD23

2003544 CD25

2003547 CD30 (Ki-1)

2003553 CD33

2003556 CD34 (QBEnd/10)

2003559 CD35

2003565 CD42b

2003568 CD43 (L60, Leu 22)

2003571 CD44

2003574 CD45 (LCA)

2003586 CD52 (CAMPATH-1)

2003589 CD56 (NCAM)

2003592 CD57 (Leu 7)

2003595 CD61 (Platelet Glycoprotein IIIA)

2003598 CD68 (KP1)

2003800 CD79A

2003806 CD117 (c-Kit)

2003809 CD123

2003812 CD138 (Syndecan-1)

test # test name

Immunohistochemistry Markers—Stain and Return2003815 CD163

2012844 CD200

2008652 c-MET

2008622 CXCL13

2003842 Cyclin D1 (SP4)

2003860 Hairy Cell Leukemia (DB.44)

2003878 Factor XIIIa (factor XIII)

2003908 Glycophorin A

2007173 Granzyme B

2003932 Herpes Virus 8

2003957 IgA

2003960 IgD

2003963 IgG

2005844 IgG4

2003966 IgM

2003975 IRF4/MUM1

2003981 Kappa Light Chains

2004519 Ki-67 (MIB-1)Also available with interpretation: test code 2007182

2003984 Lambda Light Chains

2013802 Langerin

2003993 Mast Cell Tryptase

2004014 Myeloperoxidase (MPO)

2004061 Oct-2

2004067 p21 (WAF1/CIP1)

2004522 p53

2004082 PAX5

2010787 PAX8

2004085 PD1

2012561 SOX11

2004142 TdT

2010688 TFE3

2004148 TIA-1

2004160 TRAP

2004172 Ulex Europaeus Agglutinin 1 (UEA-1)

2004184 Wilms Tumor (WT1), N-terminus


www.aruplab.com | www.arupconsult.com

ARUP LABORATORIES500 Chipeta WaySalt Lake City, UT 84108-1221Phone: (800) 522-2787Fax: (801) 583-2712www.aruplab.com

© 2018 ARUP LaboratoriesBD-TS-025, Rev 12, October 2018

ARUP is a nonprofit enterprise of the University of Utah and its Department of Pathology.

patients. answers. results. - arup laboratories...patients.answers.results. hematopathology testing...

Documents